FDA strengthens warnings on Glaxo, Roche/Biogen cancer drugs

(Reuters) - U.S. regulators strengthened the warning labels on two cancer drugs - GlaxoSmithKline Plc's Arzerra, and Rituxan, made by Biogen Idec Inc and Roche Holding AG - to reflect the risk that they can reactivate the hepatitis B virus in patients previously infected with it.

via Reuters: Health News Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://healthandfitness1blog.blogspot.com/2013/09/fda-strengthens-warnings-on-glaxo_25.html